$1.22
3.17% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Taysha Gene Therapies Inc Stock price

$1.22
-0.41 25.15% 1M
-0.79 39.30% 6M
-0.51 29.48% YTD
-1.46 54.48% 1Y
-5.55 81.98% 3Y
-18.78 93.90% 5Y
-18.78 93.90% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.04 3.17%
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Key metrics

Market capitalization $250.10m
Enterprise Value $174.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 20.96
P/S ratio (TTM) P/S ratio 30.02
P/B ratio (TTM) P/B ratio 3.50
Revenue growth (TTM) Revenue growth -46.07%
Revenue (TTM) Revenue $8.33m
EBIT (operating result TTM) EBIT $-86.62m
Free Cash Flow (TTM) Free Cash Flow $-81.60m
Cash position $139.49m
EPS (TTM) EPS $-0.38
P/E forward negative
P/S forward 42.46
EV/Sales forward 29.64
Short interest 16.25%
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Taysha Gene Therapies Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
100%

Financial data from Taysha Gene Therapies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
8.33 8.33
46% 46%
100%
- Direct Costs 1.23 1.23
39% 39%
15%
7.10 7.10
47% 47%
85%
- Selling and Administrative Expenses 27 27
2% 2%
318%
- Research and Development Expense 66 66
16% 16%
792%
-85 -85
23% 23%
-1,025%
- Depreciation and Amortization 1.23 1.23
39% 39%
15%
EBIT (Operating Income) EBIT -87 -87
21% 21%
-1,040%
Net Profit -89 -89
20% 20%
-1,072%

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
GlobeNewsWire
about 20 hours ago
DALLAS, April 04, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2025, the Compensation Committee of Taysha's Board of Directors granted fiv...
Negative
New York Post
5 days ago
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Neutral
GlobeNewsWire
29 days ago
DALLAS, March 07, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ("Taysha" or the "Company"), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on March 3, 2025, the Compensation Committee of Taysha's Board of Directors granted...
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 73
Founded 2019
Website www.tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today